HRTX Exercise Disclosure
Hensley Mark Earl · SEC Form 4 · Filed Nov 3, 2026
Exercise
Reported value range
Not reported
Hensley Mark Earl Chief Operating Officer
HRTX
Heron Therapeutics
HRTX
Transaction date
Oct 30, 2026
Public filing date
Nov 3, 2026
Filing lag
Filed 4 days later
HRTX daily price context
Close on/before transaction
$0.28
Oct 30, 2026
First close after public filing
$0.28
Nov 3, 2026
Return after filing · so far
+2.92%
Through Nov 6, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 11,770 shares
- SEC ownership
- Direct
- Transaction code
- M
- Form
- 4
- Filing identifier
- 0001193125-26-444831
Filing cohort
Transactions in this filing
Showing 3 of 3
Trades
3
Issuers
1
Estimated value
$937.72
Buys / sales
0 / 0
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Heron Therapeutics, Inc. /de/ HRTX Current | Exercise | Oct 30, 2026 | Not reported |
| Heron Therapeutics, Inc. /de/ HRTX | Disposition | Oct 30, 2026 | $937.72 |
| Heron Therapeutics, Inc. /de/ HRTX | Exercise | Oct 30, 2026 | $0 |